Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Public Storage, Inc. (PSA) said that it plans to voluntarily withdraw its securities from listing on NYSE Arca, Inc., formerly the Pacific Exchange. The company said that the securities will, however, continue to be listed on the New York Stock Exchange.
The company noted that the decision to voluntarily withdraw listing from NYSE Arca, Inc. was made to eliminate duplicative administrative requirements inherent with dual listings as a result of the NYSE Group's recent merger with Archipelago Holdings, the parent company of NYSE Arca. NYSE Arca will continue trading its securities on an unlisted trading privilege basis.
Probable Tanker: VRX
Friday, Keller Rohrback L.L.P. said that it has commenced an investigation of Valeant Pharmaceuticals International (VRX) and current and former Company executive officers and directors for potential violations related to the backdating of stock options.
Genetech and Biogen Idec announce positive results of Rituxan therapy for rheumatoid arthritis(DNA)
Gapper: Watch for DVAX on Monday
Dynavax technologies Corp. (DVAX) reveals New TOLAMBA Data.
Amgen (AMGN) on Sunday revealed that Enbrel is the first biologic with published data to show improvements in multiple measures of efficacy that were sustained in rheumatoid arthritis or RA patients completing up to nine years of therapy. According to the company, the data in Rheumatoid Arthritis suggested that Enbrel is both effective and safe in long-term use.
Koor Industries'(KOR) Lior Hannes resigns as Vice-Chairman of board of directors
Survey says, India-China trade to hit $30 bln by 2009.
Stock BUY Back Anouncements: CRVL, HYDL, TFC, AHL, PETS, GNW, USTA, EXP, XLTC, TEVA, UCO, PKI, LH, CKFR, SRDX
(RTTNews) - Friday afternoon, Commonwealth Biotechnologies, Inc. (CBTE), a contract research organization, announced the nine months financial results, reporting a loss compared to a profit last year on lower revenues.
The Richmond, Virginia-based Commonwealth Biotechnologies turned to a nine months loss of $660 thousand or $0.20 per share from a net income of $106 thousand or $0.03 per share in the comparable quarter of the prior-year.
*************************************************
(RTTNews) - Metallica Resources Inc. (MRB, MRB.TO) posted third quarter net loss of $604,777 or $0.01 per share compared to net income of $9.66 million or $0.12 per share in the prior year quarter. The decrease in net income of $10.26 million in the current period was primarily due to a onetime $10 million earn-in payment from Xstrata Plc in 2005.
******************************************
(RTTNews) - Friday, Hifn (HIFN), a provider of security processors for the networking and storage markets, said that its Chairman, President and Chief Executive Officer Christopher Kenber resigned.
The company has elected Albert Sisto, a member of the company's Board, as Chairman of the Board and will also serve as the company's interim Chief Executive Officer. Since 1998, Sisto has served as a director of Hifn. From June 1999 until May 2006, he was the President, Chairman and Chief Executive Officer of Phoenix Technologies Ltd.
*******************************************
(RTTNews) - Friday, Wacoal Holdings Corp. (WACLY), a garments and apparels company, revealed six-month financial results, reporting increased profit on higher revenues and lower expenses.
The Kyoto, Japan based company's six month net income rose to Yen 6.2 billion or US$52.7 million from Yen 4.4 billion in the year ago period.
*******************************************
(RTTNews) - Friday, Color Kinetics Inc. (CLRK) said that it has priced a public offering of 3.61 million shares of its common stock at $19.00 per share, for the net proceeds of $35.9 million. Of the 3.61 million shares, 2 million shares are offered by the company and the remaining shares are offered by selling stockholders. Certain of the selling stockholders have also granted the underwriters an option to purchase up to an additional 541,350 shares to cover any over-allotments. The company intends to use the net proceeds for working capital and general corporate purposes. The company will not receive any proceeds from the sale of shares by selling stockholders.
*****************************************
(RTTNews) - Ralcorp Holdings (RAH) Finalizes Acquisition of Cottage Bakery.
CRVL, TASR, FSL ......
CorVel (CRVL) Announces 200K Stock Buyback
********************************************************
(RTTNews) - TASER International Inc. (TASR) announced just before noon that the US District Court in the Eastern District of Louisiana granted the company's motion for summary judgment in the product liability lawsuit filed by Dardenella Gosserand against TASER.
TASER International has since spiked above Friday's narrow range on increased volume and is now up 0.25 at $9.30. The stock is trading near the middle of a one-month range.
*********************************************
(RTTNews) - Freescale Semiconductor (FSL) reported that it has shipped more than 300 million accelerometers - a major milestone in the company's long history of sensor innovation. "Freescale's acceleration sensors are in high demand for embedded systems requiring measurement of g forces, which can damage sensitive electronics components," said Demetre Kondylis, director and general manager of Freescale's Sensor & Actuator Solutions Division. The company's broad portfolio of acceleration sensor products enables embedded developers to address a diverse range of existing and emerging applications that require accurate detection of small changes in force.
***********************************************
(RTTNews) - Friday morning, Allos Therapeutics Inc. (ALTH), a biopharmaceutical company engaged in the development of small molecule drugs for cancer treatments, said it has released updated safety results from its ongoing pralatrexate or PDX Phase 1/2 clinical study. The trial was conducted in patients with relapsed or refractory Hodgkin's disease and non-Hodgkin's lymphoma or NHL. PDX is a small molecule chemotherapeutic agent that reduces the DNA building enzyme, dihdrofolate reductase. The company noted that the result was presented at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics.
The Westminster, Colorado-based company said that the ongoing Phase 1/2 trial has been designed to assess the maximum tolerated dose, dose limiting toxicities and preliminary efficacy of PDX in patients with relapsed or refractory aggressive lymphomas. During the study the subjects enrolled were administered with 135 mg/m2 of PDX without folic acid and vitamin B12 supplementation every other week. The findings revealed increased occurrence of stomatitis in patients with notable elevations in pre-treatment homocysteine or Hcy and methylmalonic acid or MMA. Patients with less than 10 mM of Hcy and MMA showed little rise in stomatitis, while Patients with Hcy and MMA less than 200 nM did not exhibit increase in stomatitis. However, the trial showed that patients with increased Hcy and MMA who developed stomatitis with PDX did not develop advanced grade stomatitis after normalization of their Hcy and MMA with folic acid and vitamin B12 supplementation. Following these observations, when the patients were given pre-treatment with vitamin supplementation of vitamin B12 and folic acid, normalization of Hcy and MMA levels mitigated the incidence of stomatitis.
Additionally, Allos stated that a pivotal Phase 2, international, multi-center, open-label, single-arm study named PROPEL has been planned on PDX. 100 evaluable patients with relapsed or refractory PTCL who have progressed after at least one prior treatment are expected to be enrolled in the study. The study in designed with the primary endpoint of objective response rate and secondary endpoints of duration of response, progression-free survival and overall survival.
Earlier in August 2006, Allos revealed it had signed an agreement with the FDA under the Special Protocol Assessment process on the design of this pivotal Phase 2 trial. Patient enrollment at 35 centers in the U.S., Canada and Europe is expected to complete by the third quarter of 2008. PDX was awarded orphan drug designation by FDA in July 2006 for the treatment of patients with T-cell lymphoma. Peripheral T-cell lymphomas or PTCLs are a biologically diverse and uncommon group of blood cancers.
ALTH is currently trading at $4.16, up $0.01 or 0.24%, on a volume of 66,018 shares.
*********************************************
APKT consolidating at $14.50 level looks like going up..........
LMRA getting close to 6 range............
Thks, Icon.
APKT $14, any news................
Jerry, this morning on NPR Market place too.. China buying gold info...
APKT going down fast $ 14.80
Mad, prediction Gold price will go up, china is buying more gold. diversifying there reserves...............
NURO $17.50
Any idea about the SIGA takeover rumor............
Boeng $15 Billion worth of contracts from US Airforce.......
Morning Icon, yep the PR is here.
SIGA Announces $2.3 Million in New Contracts with the U.S. Air Force
http://www.marketwatch.com/News/Story/Story.aspx?guid=%7B96A71874%2D18C6%2D45F9%2DAE8C%2D64F536735D2....
NEW YORK, Nov 10, 2006 (BUSINESS WIRE) -- SIGA Technologies, Inc. (SIGA : siga technologies inc com
News , chart, profile, more
Last: 3.96+0.07+1.80%
7:04am 11/10/2006
Delayed quote dataAdd to portfolio
Analyst
Create alertInsider
Discuss
Financials
Sponsored by:
SIGA3.96, +0.07, +1.8%) today announced receipt of two contracts from the U.S. Air Force for a total of $2.3 million. SIGA received a one-year, $1.4 million contract with the Air Force Medical Service for the development of counter-measures against important potential biowarfare pathogens, the Dengue viruses, and other water-related viral agents. SIGA also received a one-year, $900,000 contract to aid the USAF Special Operations Command (USAFSOC) in its development of specific anti-viral agents, focusing on orthopoxvirus targets distinct from the target that is the focus of SIGA-246, the Company's lead smallpox drug.
"We appreciate the opportunity to continue the development of these critical biological defense capabilities with our colleagues from the Air Force," said Dr. Dennis E. Hruby, Chief Scientific Officer of SIGA.
Dengue fever and Dengue hemorrhagic fever are acute febrile mosquito-borne diseases caused by one of four closely related virus serotypes of the genus Flaviviridae. The two diseases affect tens of millions of people worldwide every year and present a biodefense threat in the U.S. Currently, there is no approved drug or vaccine against Dengue, leaving troops vulnerable overseas and in areas affected by flooding.
SIGA recently announced a breakthrough in its SIGA-246 program with the successful completion of a preliminary primate trial in which the drug completely prevented smallpox disease.
About SIGA Technologies, Inc.
SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA believes that it is a leader in the development of pharmaceutical agents and vaccines to fight potential biowarfare pathogens. In addition to smallpox, SIGA has antiviral programs targeting other Category A pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses (Ebola and Marburg).
For more information about SIGA, please visit SIGA's Web site at www.siga.com.
Sorry Removing its a repost of Icon's post PRGO recall.
Mino(CEO) also mentioned there product release in the beginning of 08.
he completely messed up the CC.
HANS @ $25.6
Thks, Icon.
I bopped in @ 4.03 bought only 1200 shares
Is the party over for SIGA, really too confusing.
it looks like runs on the rumor and dies on the news......
Icon, i should have checked your post before i posted this.
Yes, you are right no PR on that Army Contract.
SIGA Army related contract info:
http://www.fbo.gov/spg/USAF/AFDW/11CONS/Awards/FA7014-07-C-0002.html
Picked the above link from Yhoo message boards.
MVIS still owns:1,750,000 LMRA shares.
Last sold on Oct 17th - shares sold: 321,910
@ $5.77
Total proceeds: $1,856,130.00
Mad, what price do you think appropriate for LMRA.......
I tried with Ameritrade and Das level II(ARCA, INET...) platform both places no shares to short..
LMRA is on a setup for dump...................
LMRA someone bought 350K shares 1 transaction.
NASDAQ Power Gainers:
STEM , ASTM, GERN, NOVL, SIRI, WFMI, NVAX
Aspen Tech Reports Q1 loss of $0.20 Per Share.
UTSI Breaking News:
(RTTNews) - UTStarcom (UTSI) Reports Voluntary Review of Equity Grants.
Hack, are you doing Phd on LMRA, you said it is ready to blow off and it did. LOL............
where to get Nasdaq Toplist, top gainers , top losers and active info.
I am currently using Direct access level2, in it i do have all of the above info but cancelling my acct. with them.